Medical Journal. A draft prepared by the FDA in which certain requirements are proposed that biosimilar drug labels will have to meet from now on will be submitted for evaluation.
Industry news
Medical Journal. A draft prepared by the FDA in which certain requirements are proposed that biosimilar drug labels will have to meet from now on will be submitted for evaluation.
recently published
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.